Studies of damaged hearts · 03
What does TB-500 cardiac research show about thymosin beta-4?
The research copy contains a short section within the larger protein studied for heart repair. The heart findings below chiefly concern animals given the larger protein. Human evidence leaves your treatment question unanswered.
What changed when blood stopped reaching mice's hearts?
A study linked to TB-500 cardiac research found more heart cells surviving in mice given thymosin beta-4 [2]. Part of each mouse heart lost its blood supply when researchers tied an artery closed. The protein stirred activity that helps cells survive, and the damaged hearts worked better. The 2004 paper reported these thymosin beta-4 findings in mice, rather than showing recovery in people.
Researchers used whole thymosin beta-4, so the larger protein produced those mouse findings. A review described other animal studies in which heart tissue survived damage better and repaired more [9]. These results explain why TB-500 cardiac research attracts interest after heart injury. Your doctor still lacks proof of human heart recovery from the copy.
Did TB-500 itself improve the pumping of mice's hearts?
Whole thymosin beta-4 improved early heart-cell survival and heart function in mice after closure of a heart artery [2]. Those results belong to whole thymosin beta-4, without equal results established for the copy. A mouse finding cannot tell how your damaged heart would respond. Human studies haven't proved improved heart recovery from the small copy.
Did animal hearts heal better after a heart attack?
Mice given thymosin beta-4 after a heart attack had fewer heart-wall tears and better heart function [10]. Another animal study reported less heart damage after thymosin beta-4 was given to circulate through the body [8]. A separate experiment found cells moving from the adult heart's outer layer and helping form new blood vessels [11]. These changes concerned animals or heart cells, so their meaning for your treatment remains uncertain.
Cells in the outer heart layer can develop into cells needed for repair. In a 2021 pig study, researchers changed repair cells in the laboratory to make thymosin beta-4 [13]. They placed those changed cells in damaged hearts, where more of the added cells remained. More heart cells grew and repair improved, but the pigs received the cells and the protein together.
Can TB-500 heart findings establish help for a patient?
Animal studies reported less heart damage with whole thymosin beta-4 [8] and fewer heart-wall tears in mice [10]. The human heart-attack trial also tested thymosin beta-4, rather than the copy. Pigs received repair cells changed to supply the protein, leaving the separate effects of cells and protein uncertain [13]. None of those findings establishes benefit from the small copy for your heart.
What is known about the people in the heart study?
According to the public trial listing, the thymosin beta-4 heart-attack study in people has finished [12]. Patient findings showing how well the hearts recovered are not reported in that listing. A study can end without establishing that treatment helped people with your illness. Whole protein was given in the trial, without proving that TB-500 benefits your heart [12].
An earlier injection study of thymosin beta-4 was withdrawn before any patient joined [12]. Nobody received treatment in that study, leaving no patient experience to assess. Animal work found better survival of heart cells [2], movement from the heart's outer layer [11], and fewer heart-wall tears [10]. Added repair cells also remained in pigs' hearts more successfully [13], but those results concerned animals.
Your doctor needs findings about how patients actually fared to judge a heart treatment. The available human evidence hasn't shown heart benefit from the small copy [12]. Public trial listings tell whether a study began or ended, without always reporting patient results. Animal healing gives reasons to study treatment, while the human recovery question still needs an answer.
Does the finished thymosin beta-4 trial prove better human recovery?
The human heart-attack trial of thymosin beta-4 is marked as finished [12]. The listing doesn't show that patients' hearts recovered better, or that the TB-500 copy would help [12]. The word finished describes the study's end, rather than a successful treatment result.